MX2022010945A - Usos terapeuticos de compuestos macrociclicos. - Google Patents
Usos terapeuticos de compuestos macrociclicos.Info
- Publication number
- MX2022010945A MX2022010945A MX2022010945A MX2022010945A MX2022010945A MX 2022010945 A MX2022010945 A MX 2022010945A MX 2022010945 A MX2022010945 A MX 2022010945A MX 2022010945 A MX2022010945 A MX 2022010945A MX 2022010945 A MX2022010945 A MX 2022010945A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic uses
- macrocyclic compounds
- compounds
- mammals
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984159P | 2020-03-02 | 2020-03-02 | |
| PCT/US2021/020255 WO2021178296A1 (en) | 2020-03-02 | 2021-03-01 | Therapeutic uses of macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010945A true MX2022010945A (es) | 2022-10-07 |
Family
ID=77613771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010945A MX2022010945A (es) | 2020-03-02 | 2021-03-01 | Usos terapeuticos de compuestos macrociclicos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250262216A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4114530A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023515687A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230022151A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115397514A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021229457A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022017425A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174455A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295938A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010945A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021178296A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111902417B (zh) | 2018-04-25 | 2023-07-28 | 北京普祺医药科技股份有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| WO2022171139A1 (zh) * | 2021-02-10 | 2022-08-18 | 北京国鸿生物医药科技有限公司 | 一种巨环化合物、药物组合物以及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| BR112018000297A2 (pt) * | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| AU2017302019A1 (en) * | 2016-07-28 | 2019-02-07 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| PT3658148T (pt) * | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| WO2021063276A1 (zh) * | 2019-09-30 | 2021-04-08 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
-
2021
- 2021-03-01 US US17/905,503 patent/US20250262216A1/en not_active Abandoned
- 2021-03-01 EP EP21764224.8A patent/EP4114530A4/en not_active Withdrawn
- 2021-03-01 CA CA3174455A patent/CA3174455A1/en active Pending
- 2021-03-01 JP JP2022552626A patent/JP2023515687A/ja active Pending
- 2021-03-01 AU AU2021229457A patent/AU2021229457A1/en not_active Abandoned
- 2021-03-01 MX MX2022010945A patent/MX2022010945A/es unknown
- 2021-03-01 KR KR1020227034099A patent/KR20230022151A/ko not_active Ceased
- 2021-03-01 WO PCT/US2021/020255 patent/WO2021178296A1/en not_active Ceased
- 2021-03-01 BR BR112022017425A patent/BR112022017425A2/pt not_active IP Right Cessation
- 2021-03-01 IL IL295938A patent/IL295938A/en unknown
- 2021-03-01 CN CN202180023879.XA patent/CN115397514A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL295938A (en) | 2022-10-01 |
| EP4114530A1 (en) | 2023-01-11 |
| WO2021178296A1 (en) | 2021-09-10 |
| JP2023515687A (ja) | 2023-04-13 |
| AU2021229457A1 (en) | 2022-10-20 |
| CA3174455A1 (en) | 2021-09-10 |
| US20250262216A1 (en) | 2025-08-21 |
| KR20230022151A (ko) | 2023-02-14 |
| BR112022017425A2 (pt) | 2022-11-29 |
| EP4114530A4 (en) | 2024-04-17 |
| CN115397514A (zh) | 2022-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007162A (es) | Macrociclos y sus usos. | |
| MX2018000718A (es) | Macrociclos de diarilo quirales y usos de los mismos. | |
| MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
| CL2023000061A1 (es) | Macrociclos y su uso | |
| ECSP034916A (es) | Oxazolidinonas substituidas para terapia de combinacion | |
| CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
| CR9672A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
| CO2020000633A2 (es) | Compuestos macrocíclicos y usos de los mismos | |
| UY33616A (es) | Compuestos con estructura de imidazotriazinona | |
| BR112023025916A2 (pt) | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
| CR20240533A (es) | Macrociclos de indazol y su uso | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| CL2024000115A1 (es) | Anticuerpos anti-hla-g | |
| CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
| MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| MX2024014995A (es) | Macrociclos que contienen indazol y su uso | |
| UY39061A (es) | Inhibidores macrocíclicos de rip2-cinasa | |
| MX2024002913A (es) | Anticuerpos anti-siglec-6 y metodos de uso de los mismos. | |
| ECSP22081741A (es) | Células t v delta1+ para el tratamiento de neoplasias mieloides | |
| MX2026000140A (es) | Compuestos macrociclicos y uso como inhibidores de tyk2 | |
| ECSP23044970A (es) | Compuestos y composiciones de moléculas pequeñas | |
| GT200700020A (es) | Compuestos y derivados de dibencilamina | |
| BR112022017425A2 (pt) | Usos terapêuticos de compostos macrocíclicos |